Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to improve stem cell transplant therapies for the treatment of hematological cancers through a trials acceleration model. Prof. Craddock outlines prospective trials, including a randomized donor leukocyte infusion (DLI) trial in patients who have undergone transplant, allogeneic/ autologous stem cell transplant trials, and trials looking into optimizing supportive patient care. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Content on www.vjoncology.com...
from BOPA 2018 is supported by Napp Pharmaceuticals Ltd